EC
FHTX icon

Euclidean Capital’s Foghorn Therapeutics FHTX Stock Holding History

Euclidean Capital’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.52M Hold
1,573,761
– – 1.92% 5
2025
Q4 		$8.5M Hold
1,573,761
– – 2.3% 4
2025
Q3 		$7.7M Hold
1,573,761
– – 3.23% 4
2025
Q2 		$7.4M Hold
1,573,761
– – 2.42% 4
2025
Q1 		$5.74M Hold
1,573,761
– – 2.16% 3
2024
Q4 		$7.43M Hold
1,573,761
– – 1.01% 5
2024
Q3 		$14.7M Hold
1,573,761
– – 1.62% 4
2024
Q2 		$9.05M Hold
1,573,761
– – 1.14% 3
2024
Q1 		$10.6M Hold
1,573,761
– – 1.35% 5
2023
Q4 		$10.2M Hold
1,573,761
– – 1.14% 6
2023
Q3 		$7.87M Hold
1,573,761
– – 1.72% 8
2023
Q2 		$11.1M Buy
1,573,761
+312,500
+25% +$2.19M 2.85% 6
2023
Q1 		$7.82M Hold
1,261,261
– – 6.86% 5
2022
Q4 		$8.05M Hold
1,261,261
– – 7.53% 6
2022
Q3 		$10.8M Hold
1,261,261
– – 10.05% 3
2022
Q2 		$17.2M Hold
1,261,261
– – 14.59% 3
2022
Q1 		$19.2M Hold
1,261,261
– – 11.16% 3
2021
Q4 		$28.8M Hold
1,261,261
– – 16.4% 2
2021
Q3 		$17.6M Hold
1,261,261
– – 8.54% 5
2021
Q2 		$13.5M Hold
1,261,261
– – 4.37% 8
2021
Q1 		$16.6M Hold
1,261,261
– – 5.56% 6
2020
Q4 		$25.6M Buy
+1,261,261
New +$24.2M 5.41% 5

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Euclidean Capital's FHTX Position: Q1 2026 in Review

Euclidean Capital held its Foghorn Therapeutics (FHTX) position steady in Q1 2026 at 1,573,761 shares worth $7.52M. The position accounts for 1.92% of the portfolio, ranked #5.

Euclidean Capital first reported a position in FHTX in Q4 2020 and has held it in 22 quarters since. The position peaked at $28.8M in Q4 2021. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Euclidean Capital held 1,573,761 shares of Foghorn Therapeutics worth $7.52M as of Q1 2026.
  • Euclidean Capital left its Foghorn Therapeutics share count unchanged in Q1 2026.
  • Foghorn Therapeutics made up 1.92% of Euclidean Capital's portfolio in Q1 2026, its #5 holding.
  • Euclidean Capital first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Euclidean Capital's Foghorn Therapeutics position peaked at $28.8M in Q4 2021.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Euclidean Capital's 13F filing for Q1 2026, filed 15 May 2026.